Nyxoah SA (NASDAQ:NYXH) announced the first patient implantation in BREATHE on September 7. The prospective, single-arm U.S. post-approval study will evaluate Genio hypoglossal-nerve stimulation in adults aged 22 or older with moderate to severe obstructive sleep apnea for whom standard-care treatments have failed, cannot be tolerated, or are unsuitable. Plans call for up to 229 patients at up to 25 centers, with follow-up lasting up to five years.
For Nyxoah SA, the milestone begins a new phase of evidence collection following Genio’s August 2025 FDA approval. The co-primary effectiveness endpoints are apnea-hypopnea-index and oxygen-desaturation-index responder rates at 12 months. Device- and procedure-related serious adverse events will be assessed at 12 months and annually thereafter. The investment question is whether that evidence can help turn clinical credibility into sustained commercial adoption.
Bull Case
Nyxoah SA has an opportunity to demonstrate how Genio performs across different physicians and treatment settings. Consistent outcomes across participating centers could give referring sleep physicians and implanting surgeons greater confidence in patient selection and treatment delivery.
The product offers a distinct approach. Genio stimulates hypoglossal nerves on both sides of the tongue, using a battery-free implant powered by an external wearable. For Nyxoah SA, documenting effectiveness and safety in routine practice could help physicians assess how that design fits their patients’ needs.
Longer follow-up could also strengthen the evidence available to payers. Nyxoah SA could use sustained responses and safety findings to support coverage discussions, while participating centers gain practical experience with implantation and follow-up. That would make BREATHE valuable beyond a single headline response rate.
The commercial opportunity is therefore to reduce uncertainty along the treatment pathway. If physicians become more comfortable recommending Genio and reimbursement supports procedures, Nyxoah SA could build a more repeatable source of implant demand.
Bear Case
BREATHE has no randomized control group. Nyxoah SA can assess outcomes after implantation, but the design cannot establish comparative superiority over competing stimulation systems or other sleep-apnea treatments. Patient selection and differences in care between centers will also matter when interpreting results.
The first implantation establishes study initiation, not a clinical outcome. Enrollment will take time, and each patient must reach the relevant follow-up window. For Nyxoah SA, keeping participants engaged over several years is important because missing assessments and withdrawals can complicate conclusions about durability and safety.
Commercial execution remains a separate test. Insurance coverage for Genio varies by plan and policy. Nyxoah SA also depends on referral pathways, trained implant teams, and follow-up capacity. Encouraging clinical results would not automatically resolve those constraints.
Investors should distinguish research enrollment from commercial momentum. The first-patient announcement did not quantify incremental revenue, reimbursement approvals, or commercial procedure growth attributable to BREATHE. Nyxoah SA will need operating evidence alongside study updates to demonstrate that greater clinical familiarity translates into paid adoption.
Hedge Fund Sentiment
The filings available so far reflect positions held before Nyxoah SA reported the first patient implantation in BREATHE. Insider Monkey’s database showed 8 hedge funds holding Nyxoah SA at the end of 2Q2026, up from 5 funds three months earlier.
Conclusion
BREATHE is strategically useful, but Nyxoah SA has announced an evidence-building milestone rather than new outcome data. Enrollment, 12-month responder rates, adverse events, reimbursement progress and commercial procedure volumes will determine its investment significance. Consistent outcomes could support Genio adoption, provided implant centers and payers can turn that confidence into accessible treatment.
READ NEXT: Guidewire (GWRE) Grew Fiscal 2026 ARR 19%. Can Cloud Economics Offset Slower Near-Term Growth? and Asana (ASAN) Reached a 10% Non-GAAP Operating Margin. Can Agentic Products Restore Expansion?
This article is originally published at Insider Monkey.
